Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22700400 | 0.90 | MAPT (0.36) | SMN1; SMN2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL22700398 | 0.89 | MEN1 (0.35) | ALDH1A1KMT2A | |
| SCHEMBL22700375 | 0.84 | KDM4E (0.41) | SMN1; SMN2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL22686504 | 0.81 | ALB (0.42) | SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL22700418 | 0.80 | MAPT (0.41) | SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL22700390 | 0.79 | MCL1 (0.50) | SMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL22700775 | 0.79 | MAOA (0.36) | SMN1; SMN2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL22700720 | 0.79 | MAPT (0.42) | SMN1; SMN2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL22700489 | 0.78 | BCL2 (0.40) | KMT2A | |
| SCHEMBL22700415 | 0.78 | AKR1B1 (0.35) | SMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200369618-A1 | ASYMMETRIC DERIVATIVES OF POLYPHENOLS OF THE DINAPHTHALINE SERIES, PROCESS OF PREPARING AND USE THEREOF | Nearmedic International Limited (CY) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369618-A1 | ASYMMETRIC DERIVATIVES OF POLYPHENOLS OF THE DINAPHTHALINE SERIES, PROCESS OF PREPARING AND USE THEREOF | DNM2, DNM1, MAVS | SMN1; SMN2 2649/4885TSHR 4837/4885ALDH1A1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.